Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled:AVXL -The Stock and the Market 09/26/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 317
Posts 40,607
Boards Moderated 29
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
XenaLives Member Level  Thursday, 09/26/19 10:15:20 AM
Re: None
Post # of 232263 
Compiled:AVXL -The Stock and the Market 09/26/19
___________________________________________________________________________________________________

Historic short interest:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151367871

Chart illustration of shares shorted summer 2019
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151145245

Historical chart study comparing AVXL to AMRN and ARWR
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150959901
Comment on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150960121

9/16/19 observation on options movement
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151152660

AMRN - AVXL stock comparison:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145046917

"Anavex in Five Years", perspective from falconer66a
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148898022

Will Anavex business model include a novel development in precision medicine?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148557900

Discussion on 4/25/19 concerning new blood tests for Alzheimer's - read forward from here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148425843

How the pros take out stops...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150305491

Missling expertise in M&A roundtable :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150852768

Anavex in stealth mode:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150311481

Evaluation of market cap potential of AVXL:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143725918

Interesting look at what was expected of AVXL in 11/14:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475152

Retrospective look at Missling's appointment as CEO:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475334

2015 interview of Missling stating that knowledge will be the goal of the 2a adaptive trial which will increase our chance of success:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475720

Prediction that AVXL would reverse Alzheimer's from 2013:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475575

Missling without quite so much hair here:
http://spotlightonbioadvances.homestead.com/Case-Study.html

How Missling is using the old FDA process to create new precision medicine processes:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148611726

Biostock's AI program estmates 89% chance of approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148688289

Little Orphan Anavex - a 2016 post...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=122025509

Historical short interest:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145900941

Hint at actual AVXL value:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147273799

F1ash statements on the Cantor ATM:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146081099

Charts showing periods of institutional accumulation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144037184

Gross market estimates from falconer66a:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145757480

Pharma growth predictions (from Talon38)
https://www.biospace.com/article/deloitte-predicts-pharma-growth-driven-by-orphan-disease-drugs-and-external-deals

MycrolftHolmes on Barriers to investment in AVXL:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135326763

Short interest note from georgejjl:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147068381

Perspective on how quickly Anavex could morph into a profitable entity , making further dilution unnecessary. This may provide urgency for institutions to establish a position where stock has limited liquidity resulting in a pre-approval ramp up of pricing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143560772



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist